echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Focus on microbial drug research and development Unknown Jun Bio completed tens of millions of dollars in B-plus round of financing

    Focus on microbial drug research and development Unknown Jun Bio completed tens of millions of dollars in B-plus round of financing

    • Last Update: 2020-12-29
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Industry came the news that a Chinese company focused on micro-ecological pharmaceutical - Shenzhen Unknown Jun Biotech Co., Ltd. ("Unknown Jun Bio") recently completed tens of millions of dollars of B-plus financing, led by Chunhua Capital and Sgao Capital, Wuyuan Capital (formerly Morningside Capital), Junlian Capital, Yumei Capital and Ya billion Capital.
    it is understood that the current round of financing funds will be mainly used for the company's 2021 drug clinical trials, new drug pipeline research and development and the existing technology platform for continuous research and development and expansion.
    it's worth noting that this month, the MIT Technology Review released its annual list of "50 Smart Companies" (TR50), and unknown creatures were selected.
    , it is known that unknown junbio has reached the international leading level of predictive accuracy for cancer patients receiving PD-1 treatment through a predictive model using gut microorganisms as biomarkers.
    According to the award speech, Unknown Monarch has more than 340,000 microbial and disease-related data, combined with self-research machine learning algorithms, can accurately predict the composition of the bacteria on the host gene level regulation, guide drug research and development and clinical application.
    Unknown Jun Bio was founded in 2017, founded by Dr. Tan, the company is committed to intestinal micro-ecological-based, AI technology-based, precision management of human intestinal health, known as "China's first intestinal microbial AI pharmaceutical company."
    2018, Unknown Creatures was named fast company's "Top 50 Best Innovation Companies in China 2018" list by Fast Company magazine.
    as one of the few innovative companies in China to lay out intestinal microbial pharmaceuticals, Unknown Jun Bio has been favored by many well-known venture capital institutions.
    since its inception, Unknown Monarch has completed a total of 10 million U.S. dollars in rounds of A-round and A-plus financing, as well as more than 100 million yuan of rounds of B-round financing.
    the B-plus financing is another significant development in the capital sector after the company completed the RMB 100 million B round of financing led by Junlian Capital in November 2019.
    Public information shows that, unlike the traditional "cell-animal model-human" path of medical research and development, Unknown Jun Bio adopts an innovative scientific research model and a unique drug research and development platform, combining "artificial intelligence and bioinfocus analysis technology" with intestinal micro-ecological technology to greatly improve the efficiency and success rate of new drug research and development.
    years, intestinal micro-ecological pharmaceutical has become a hot research field in the pharmaceutical industry.
    trillions of microbes in the human gut.
    Studies have shown that the gut microbiome plays an important role in the occurrence and progression of a variety of diseases, in addition to affecting local intestinal diseases such as inflammatory bowel disease (IBD), they can regulate the response to cancer immunotherapy, affect the treatment of Parkinson's disease, and may have an effect on a variety of mental illnesses, including autism.
    intestinal bacteria in healthy human faeces is one of the most desirable treatments available.
    method, known as dung transplantation, was written in the U.S. Medical Guidelines in 2013.
    , global research and development of micro-ecological drugs is on the fast track.
    , the clinical progress of bacterios transplantation (FMT) treatment is advancing rapidly, and the existing drugs have successfully completed Phase 3 clinical trials, and the first bacterios transplant drug is expected to be approved by the FDA by the end of this year or next year.
    at the same time, the global field has been formulated bacteria drugs gradually into clinical phase 2, bacterial metabolites drugs gradually into clinical phase 1.
    Unknown Jun Bio is also making full efforts to promote the development of pipeline progress, its own drug pipeline includes anti-PD-1 tumor immunotherapy, autism, aGvHD (transplant anti-host disease) and other adaptation direction, and has carried out intestinal micro-ecological clinical research cooperation with a number of medical institutions, many micro-ecological drugs in clinical research showed significant therapeutic effect.
    Among them, the company's joint treatment project of bacteriovirus transplantation (FMT) and anti-PD-1 inhibitors in cooperation with Peking University Cancer Hospital, as well as the clinical research on the treatment of autistic patients through bacterios transplantation with Shanghai Xinhua Hospital, have entered the human trial stage, and obtained better early trial data.
    , the company also collaborated with Southern Medical University Southern Hospital on the intestinal bacterioscapotic capsule therapy aGvHD project.
    October 2020, Unknown Monarch submitted an application to the FDA for a new drug clinical trial (IND) for aGvHD.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.